Every 10-Q that Pulmonx Corporation (LUNG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LUNG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LUNG filings page.
Pulmonx Corporation, a commercial-stage medical technology company focused on minimally invasive treatments for severe emphysema, reported Q2 2026 revenue of $22.8 million, slightly below $23.9 million a year earlier. Gross margin improved to 78.0% from 72.1%.
Net loss narrowed to $10.1 million in Q2 2026 from $15.2 million in Q2 2025, and to $23.7 million for the first half of 2026 from $29.6 million a year prior. As of June 30, 2026, cash and cash equivalents were $55.8 million, with $37.5 million of term loans and credit agreements outstanding and an accumulated deficit of $545.3 million. Management states that existing cash resources are expected to support operations for at least the next 12 months.
During 2026 the company repaid its prior $37.0 million CIBC term loan and entered into a new senior secured facility with Perceptive for up to $60.0 million, drawing $40.0 million at closing and issuing equity warrants in connection with the financing.
Pulmonx Corporation reported Q1 2026 results showing continued growth investment and operating losses. Revenue was $20.6 million versus $22.5 million a year earlier, with gross margin improving to 77.9%. The company posted a net loss of $13.7 million, or $0.33 per share, and an accumulated deficit of $535.2 million.
Pulmonx ended the quarter with $61.6 million in cash and cash equivalents and 42.2 million shares outstanding. It refinanced its prior CIBC facility with a new $40.0 million senior secured term loan from Perceptive, maturing in 2031 and partly bearing paid-in-kind interest, and issued related common stock warrants.